Author details

Full Name

Alex Toker

Affiliation

ORCID

Career Start Year

1990

Papers

140

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37480742	Generative artificial intelligence in Journal of Biological Chemistry.		2023
36409824	JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.	Cancer Res	2023
37673340	PI3K signaling through a biochemical systems lens.		2023
35243242	The KRAS-G12D mutation induces metabolic vulnerability in B-cell acute lymphoblastic leukemia.	iScience	2022
35896750	PI3K drives the de novo synthesis of coenzyme A from vitamin B5.	Nature	2022
34923237	Can open science follow open access?	Journal of Biological Chemistry	2022
34762647	Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype.	PLoS Genet	2021
34737445	FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance.	Nat Cell Biol	2021
34911776	Can Improved Use of Biomarkers Alter the Fate of PI3K Pathway Inhibitors in the Clinic?	Cancer Research	2021
34907909	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.	Journal of Clinical Investigation	2021
33049205	Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer.	Cancer Cell	2020
32139506	Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy.	Journal of Biological Chemistry	2020
31859249	Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling.	Cell Chem Biol	2020
32645038	Metabolic pathway alterations in microvascular endothelial cells in response to hypoxia.	PLoS ONE	2020
32513774	The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.	Cancer Discov	2020
30692625	AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions.	Nat Cell Biol	2019
31699922	Double trouble for cancer gene.	Science	2019
29203461	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.	Cancer Discov	2018
30241602	PI 3-Kinase Signaling: AKTing up inside the Cell.	Molecular Cell	2018
29535262	Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.	Science Signaling	2018
28223411	Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.	Science Signaling	2017
28431241	AKT/PKB Signaling: Navigating the Network.	Cell	2017
28343126	PI3K signaling in cancer: beyond AKT.	Current Opinion in Cell Biology	2017
28373060	Cross-talk between the CK2 and AKT signaling pathways in cancer.	Advances in Biological Regulation	2017
29259101	Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.	Science Signaling	2017
28255083	Adaptive Reprogramming of Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer.	Cancer Discovery	2017
27940576	Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.	Cancer Res	2017
28049764	The SCFÎ²-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis.	Sci Signal	2017
27626181	LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.	Oncotarget	2016
26838061	Nonessential amino acid metabolism in breast cancer.	Advances in Biological Regulation	2016
27237051	Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.	Molecular Cell	2016
27004402	Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.	Oncotarget	2016
27088857	Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer.	Nat Cell Biol	2016
27563096	pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner.	Science	2016
26027929	MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy.	Cell Rep	2015
25750731	The phosphoinositide 3-kinase pathway and therapy resistance in cancer.	F1000Prime Reports	2015
25735562	NFAT1 promotes intratumoral neutrophil infiltration by regulating IL8 expression in breast cancer.	Mol Oncol	2015
26267528	PIPPing on AKT1: How Many Phosphatases Does It Take to Turn off PI3K?	Cancer Cell	2015
26293922	PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.	Cancer Discovery	2015
24838891	PTEN-deficient tumors depend on AKT2 for maintenance and survival.	Cancer Discov	2014
25458846	SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.	Molecular Cell	2014
24269953	The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration.	Mol Cancer Res	2014
24335962	Targeting Akt3 signaling in triple-negative breast cancer.	Cancer Res	2014
25233414	Signalling specificity in the Akt pathway in breast cancer.	Biochemical Society Transactions	2014
24813709	Akt-ing up on SRPK1: oncogene or tumor suppressor?	Molecular Cell	2014
24670654	Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus.	Nature	2014
24794538	Signaling specificity in the Akt pathway in biology and disease.	Advances in Biological Regulation	2014
23288461	Using phospho-motif antibodies to determine kinase substrates.	Current Protocols in Molecular Biology	2013
23135917	RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.	Cancer Research	2013
21986444	Achieving specificity in Akt signaling in cancer.	Advances in Biological Regulation	2012